ixekizumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
References 1 Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog…
Interleukin(IL)‐17 inhibitors display higher efficacy than both TNFi and IL‐12/23i, which increased the goal psoriasis area…
BACKGROUND
Data concerning clinical experience in real world setting with ixekizumab for psoriasis are still exiguous and aim of…
Psoriasis is a systemic disease with numerous concomitant metabolic disorders. Apparently, T‐helper 17 lymphocytes and…
Editor Psoriasis vulgaris (plaque psoriasis) is a chronic, painful and debilitating skin disorder that negatively impacts health…
Background Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A…
BACKGROUND
Monoclonal antibodies that target both Interleukin (IL)-12 and IL-23 have shown great efficacy in the treatment of…
Early identification of responsiveness to biologic treatments in psoriasis has significant clinical and economic implications.
On April 2, Amgen in Thousand Oaks, California, and AstraZeneca in London, announced a partnership to develop five monoclonal…